👉Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia ☝️ Due to the rarity of the condition, challenges continue to exist regarding diagnostic ambiguity, underdiagnosis and misdiagnosis due to asymptomatic presentation or symptom misattribution.

"α-cell Gs signaling is required for the release of glucagon and insulin after consumption of a mixed meal." Fantastic collaborative work by a stellar group in Liu Liu Min Chen, Wess, Lee S Weinstein, Merrins, JE Campbell et al.

👉Inflammation, Colchicine, and Atherosclerotic Disease Is Familial Mediterranean Fever an Exception That Proves the Rule? ☝️The broad use of continuous lifelong colchicine in the setting of FMF provides us with optimism that uptake of colchicine for the secondary prevention of

The SR-B1ΔCT/LDLR KO mouse represents an easily maintained, diet-inducible animal model of coronary atherosclerosis that rapidly develops occlusive, fatal atherosclerotic CHD 🔗atherosclerosis-journal.com/article/S0021-… Yuanjia Zhu, MD, PhD Stefan Elde, MD Elsevier Cardiology European Atherosclerosis Society

There is the need to evaluate levels of circulating ApoB, in association to LDL-C and non-HDL-C, as marker of cardiovascular risk in diabetic patients not only in tertiary care settings. Read this review to know why 👉 atherosclerosis-journal.com/article/S0021-… Elsevier Cardiology European Atherosclerosis Society #CVPrev

Pathogenesis of liver steatosis in type 2 diabetes. #MASLD #MASH Diabetologia link.springer.com/article/10.100…

👉Advances in Targeting LDL Cholesterol: PCSK9 Inhibitors and Beyond 👏 Outstanding article, great authors, must-read!!! ☝️Multiple advanced treatments are currently available to address residual atherogenic lipoprotein risk beyond statin therapy. With every approximately 40

An illustration of mine showing the lipolytic complexities of TG-containing VLDL-apoB particles in a 2018 manuscript. linkinghub.elsevier.com/retrieve/pii/S… National Lipid Association European Atherosclerosis Society

Thread of the most surreal beaches on Earth 1. Pathway to Atlantis, Thailand

NSW CVRN is exited to bring back the HEART Pitch, a 3-minute research pitch competition for PhD Candidates and EMCRs. Enter for your chance to win a $1,000 prize! Applications close on 2 September 2024. View details and apply here: shorturl.at/Zr3Rd

We are also excited to showcase two of our past presidents as this year’s invited national speakers. We will hear from our very first female president, Prof. Kerry-Anne Rye from UNSW who will speak on “Current and future therapeutic options for reducing cardiometabolic disease”.

Many thanks to Almut Schulze 🧬🔬 and Alina Wahl from DKFZ for their wonderful News & Views @NatureCellBiol on our recently published article on ZEB1-mediated ferroptosis sensitivity through regulation of lipogenic enzymes. Check it out here: doi.org/10.1038/s41556… #ferroptosis

☝ Inflammation and Atherosclerosis: Prospects for Clinical Trials 👉 Targeting inflammation and immunity offers the possibility of an orthogonal approach that may address the residual risk encountered in individuals with well-controlled lipid profiles. 👉Ultimately, addressing

40 Years On: Still Arguing About Statins 🗣️ In the 1980s, some of the ongoing debate related to Statins was starting to settle. The early days of cholesterol-lowering was rejected not by contrarians, but by mainstream cardiologists. One of the core trials to change the tune was

👉Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis It's clear that Lp(a) is a structurally complex molecule with unique biological functions. It plays a significant role in the inflammatory process through various mechanisms,

✔️ Our final workshop of 2024 was a success! Thanks to the participants who joined us at UConn Health to learn in-demand surgical procedures in lab mice from The Jackson Laboratory experts. Looking for training in 2025? Explore JAX Courses & Workshops ➡️ jax.org/education-and-…

We recently reported updated durability data from the Heart-1 clinical trial of VERVE-101 at #ESGCT. In the single participant in the highest dose cohort, LDL-C reduction has been sustained out to 18 months after the single dose. These new durability data further support the

Seeing the LDL (the bad cholesterol) structure, with its apoB100 component, bound to its receptor, for the first time, thanks to cryo-EM and #AlphaFold2 nature nature.com/articles/s4158… nature.com/articles/s4158… C. Keith Cassidy

To mark the occasion of FDA approving another APOC3 targeting drug to reduce circulating triglycerides in a rare disease (familial chylomicronemia syndrome), let me share this pedigree chart of a large extended family of APOC3 knockouts from Pakistan. The index patient (marked by

👉 New Study on Lipoprotein(a) & Thrombosis! 🔬 A large genetic study (410,177 participants) found that Lp(a) is strongly associated with myocardial infarction (MI) but NOT with venous thromboembolism (VTE). ❌ Key finding: The risk of MI linked to Lp(a) is not due to